Recent Updates — GUTS
Fractyl Health announced a strategic reprioritization to concentrate resources on its lead product candidate, Revita, following positive pivotal results from the REMAIN-1 trial. The company will reduce its workforce by approximately 45% and discontinue internal development of its Rejuva gene therapy program while seeking strategic alternatives for that asset. Jay Caplan retired as President and Chief Product Officer effective October 30, 2026, with CEO Harith Rajagopalan assuming the President role. The company estimates $2 million in severance charges and expects quarterly cash burn to drop by roughly 50% to approximately $8 million by Q2 2027, extending its cash runway into mid-2027. Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes.
Fractyl Health announced positive topline six-month results from the REMAIN-1 Pivotal Cohort, a randomized, double-blind, sham-controlled study evaluating the Revita DMR System for maintaining weight loss after GLP-1 therapy discontinuation. The trial met its co-primary endpoint with high statistical significance (p=0.0023), showing that Revita participants retained approximately 80% of their GLP-1-induced weight loss compared to 67% in the sham group. Additionally, 32% of Revita patients were weight stable or had further weight loss at six months versus 18% for sham. The company plans to submit a De Novo marketing application to the FDA in late Q4 2026 and expects topline one-year data in Q1 2027. Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes.
Fractyl Health, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on September 30, 2026, to effect a one-for-twelve (1-for-12) reverse stock split of its outstanding common stock. The amendment was approved by stockholders at a Special Meeting held on September 24, 2026, and subsequently authorized by the board of directors on the same date. The reverse split will become effective at 5:00 p.m. Eastern Time on October 2, 2026. Under this action, every twelve shares of common stock will be combined into one share without a change in par value. Proportionate adjustments will apply to outstanding stock options, restricted stock units, and warrants, while fractional shares will be cashed out. Trading on the Nasdaq Global Market is scheduled to resume on a split-adjusted basis on October 5, 2026. Fractyl Health operates in the biotechnology industry, focusing on developing therapies for metabolic diseases.
Fractyl Health, Inc. held a Special Meeting of Stockholders on September 24, 2026, where shareholders approved a series of alternate amendments to the Certificate of Incorporation. This approval authorizes the Board of Directors to effect a reverse stock split of common stock at a ratio ranging from 1-for-5 to 1-for-15, with the specific ratio to be determined by the Board in its sole discretion. The proposal received 102,476,581 votes for, 9,319,450 against, and 191,821 abstentions out of approximately 70.35% voting power represented. Fractyl Health operates in the biotechnology industry, focusing on developing therapies for metabolic diseases.
Fractyl Health, Inc. received notification from Nasdaq on September 10, 2026, that its common stock is subject to delisting because the minimum bid price remained below $1.00 for 30 consecutive business days and failed to regain compliance within the 180-day grace period. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the outcome. To address the deficiency, Fractyl filed a proxy statement on August 24, 2026, seeking shareholder approval for a reverse stock split with a ratio ranging from 1-for-5 to 1-for-15. The company operates in the healthcare sector, specifically developing therapies for metabolic diseases.
Fractyl Health reported second quarter 2026 financial results and provided clinical updates. The company posted a net loss of $25.5 million, compared to $27.9 million in the prior year period, driven by reduced R&D expenses of $13.8 million against $21.2 million previously. Cash and cash equivalents stood at approximately $47.1 million as of June 30, 2026, with management projecting a cash runway into early 2027. Clinically, one-year data from the REMAIN-1 Midpoint Cohort showed Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% for sham controls. Topline six-month randomized data from the REMain-1 Pivotal Cohort is expected in early Q4 2026, potentially paving the way for an FDA De Novo submission later that quarter. Fractyl Health operates in the biotechnology and medical device industry, developing procedural therapies and gene treatments for obesity and type 2 diabetes.